
The treatment of cardiovascular, metabolic and malignant diseases is playing an increasing role in HIV-infected patients. Intensified cancer screening is recommended, but data demonstrating a reduction of tumour incidence or tumour-associated mortality are rare. Controversy exists about the best time point of initiation of antiretroviral therapy. Recently, data indicate that an earlier start could reduce HIV transmission.

